Kisspeptins are a group of peptides (chains of amino acids) that stimulate the release of Gonadotropin Releasing Hormone (GnRH) from the pituitary gland in the brain and is involved in the regulation of developmental sex hormones at the beginning stages of puberty. Kisspeptin peptides stimulate gonadotropin release in both men and women and are critical in fertility and are potential therapies for infertility.
Similarly, to Human Chorionic Gonadotropin (HCG), Kisspeptins have shown therapeutic benefits due to increasing internal production of Luteinizing Hormone (LH) and Follicular Stimulating Hormone (FSH). This increase in LH can stimulate Leydig cells in our testicles to produce testosterone without the result of hypogonadism shown when using synthetic testosterone alone. This mechanism can help combat the effects of hypogonadism (testicular failure) as a result of deficient GnRH. Kisspeptin has been shown to be an effective alternative to HCG in both preventing testicular atrophy and maintaining or increasing testosterone and sperm production in males.
In a study February 2020, Imperial College London researchers found the hormone Kisspeptin can alter neural connections to enhance libido. Thirty-three men were given Kisspeptin one day, a placebo another. Then they entered an MRI machine and were shown provocative images. The men had increased activity in key brain pathways linked with sexual function and arousal on Kisspeptin, meaning the hormone can be used for low libido and other sexual arousal disorders.